Double Blow for Hims & Hers: SEC Investigations and Weak Outlook Send the Stock into Free Fall
Reading Time: 3 minutes
The US telemedicine provider Hims & Hers reported solid revenue growth for the fourth quarter of 2025 on Monday evening. However, a new risk weighs much heavier for investors than the margin numbers: The US Securities and Exchange Commission (SEC) is investigating the communications surrounding copied weight loss injections. At the same time, the outlook is disappointing. The stock plunged in after-hours trading. SEC investigation puts "compounded semaglutide" in the spotlight In its latest 10-K annual report, the company revealed that...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
